The lack of therapeutic benefit of adding hydroxyurea to highly active antiretroviral therapy (HAART)

J Acquir Immune Defic Syndr. 2002 Jul 1;30(3):363-4. doi: 10.1097/00126334-200207010-00014.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antiretroviral Therapy, Highly Active*
  • CD4 Lymphocyte Count
  • Case-Control Studies
  • HIV Infections / drug therapy*
  • HIV Infections / immunology
  • Humans
  • Hydroxyurea / therapeutic use*
  • Retrospective Studies

Substances

  • Hydroxyurea